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Abstract Patients with venous thromboembolism (VTE)
are prone to the development of both short-term and longterm complications that can substantially affect their
functional capacity and quality of life. Patients with deep
vein thrombosis (DVT) often develop recurrent VTE or the
post-thrombotic syndrome, whereas patients with pulmonary embolism (PE) can develop long-term symptoms
and functional limitations along a broad spectrum extending to full-blown chronic thromboembolic pulmonary
hypertension. Clinicians who care for patients showing
severe clinical manifestations of DVT and PE are often
faced with challenging decisions concerning whether and
how to escalate to more aggressive treatments such as those
involving the use of thrombolytic drugs. The purpose of
this chapter is to provide guidance on how best to individualize care to these patients.
Keywords Venous thromboembolism  Pulmonary
embolism  Thrombolytic therapy  Anticoagulants  Direct
oral anticoagulants (DOAC)  New oral anticoagulants
(NOAC)

Introduction
Venous thromboembolism (VTE), which includes deep vein
thrombosis (DVT) and pulmonary embolism (PE), continues to impose a substantial health burden upon patients and
society. A recent US population-based study estimated the
age- and sex-adjusted annual VTE event rate over the period
1985–2009 to be 142 per 100,000 persons, of which 50 %
presented as lower extremity DVT alone, 30 % PE alone,
and 20 % DVT and PE [1]. A Pediatric Hospital Information
Systems analysis noted that 1 in 200 hospitalized children
has an admission or discharge diagnosis code for VTE [2].
In 2008, the US Surgeon General estimated that over
100,000 deaths from PE occur yearly in the US, and named
PE as the most preventable cause of death in hospitalized
patients [3]. Despite advances in diagnosis and management, in-hospital mortality for acute PE approaches 7 %
overall and 32 % in those presenting with hemodynamic
instability [4]. Right ventricular (RV) dysfunction and elevations in cardiac troponin correlate with increased risk of
in-hospital death and clinical deterioration [5].
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Patients with PE or DVT are also prone to the development
of long-term complications. First, recurrent VTE events are
frequent and constitute approximately 25 % of all VTE
events [1]. Patients who suffer unprovoked VTE have a
substantial risk of recurrence that exceeds 50 % over
10 years if not treated with extended duration anticoagulation [6]. Even patients who suffer VTE in the setting of
reversible provoking factors have a long-term risk of
recurrence that exceeds 20 % over 10 years [6]. A recent
analysis of the Danish National Registry of Patients
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demonstrated that patients with VTE had increased mortality over 30 years of follow-up and that recurrent PE
remained an important cause of death throughout this time
interval [7].
In addition, within 2 years of DVT diagnosis, approximately 40 % of adult patients with a symptomatic firstepisode DVT will develop the post-thrombotic syndrome
(PTS) [8]. PTS commonly manifests as chronic limb pain,
swelling, heaviness, and/or fatigue, and progresses to stasis
dermatitis or limb ulceration in a minority of these patients
[8, 9]. PTS also occurs in approximately 25 % of children
and adolescents with extremity DVT [10]. Among survivors of PE, many will develop cardiopulmonary dysfunction and/or reduced exercise tolerance, with 4 %
developing debilitating chronic thromboembolic pulmonary hypertension (CTEPH) [11].
Clinicians who care for patients showing severe initial
clinical manifestations of PE or DVT are frequently faced
with difficult decisions concerning whether and how to
escalate to more aggressive therapeutics that incorporate
the use of thrombolytic drugs to mitigate short-term and
long-term risks.

Methods
The goal of this chapter is to provide guidance to providers
on how best to individualize care to these patients, with
specific focus on the questions listed in Table 1. Questions
were developed by consensus from the authors.
To address these questions, the published literature was
reviewed by searching electronic databases (PubMed,
Medline) and the authors’ personal libraries, with a focus on
high quality cohort studies and randomized controlled trials
(RCTs) published in the last 10 years, when available. The
authors’ consensus interpretation of these studies, in the
context of the realities of VTE care, was distilled into the
practical recommendations that are presented in this article.

Guidance

Thrombolytic therapy for acute PE functions as a
‘‘medical embolectomy’’ with the goals of reducing
thromboembolic burden, pulmonary vascular resistance,
and right ventricular dysfunction, and more rapidly restoring pulmonary capillary blood flow and effective gas
exchange than anticoagulation alone (Table 2) [12–15]. In
this manner, thrombolytic therapy may reduce mortality in
patients with massive [16] and submassive PE [17], help
prevent the development of CTEPH [18, 19] and preserve
the normal hemodynamic response to exercise [20].
Thrombolytic therapy more rapidly relieves symptoms from
PE than anticoagulation alone and may result in improved
quality of life [21]. Thrombolysis may also prevent recurrent PE by dissolving the reservoir of thrombus that often
remains in the lower extremities or pelvis.
Thrombolytic therapy for acute DVT can be performed
to reduce thrombus burden [22, 23], restore venous
patency, and reduce venous congestion, which can achieve
important therapeutic goals in selected patients: (1) save
life, limb, or organ when used urgently in patients with
DVT causing acute limb-threatening circulatory compromise (i.e. phlegmasia cerulea dolens) or progressive IVC
thrombosis causing an elevated PE risk or visceral organ
compromise [24]; (2) enable faster relief of presenting
symptoms in patients who exhibit clinical or anatomic
progression despite the initial use of anticoagulant therapy
[25]; and possibly (3) prevent late venous obstruction and
valvular reflux, which are key contributors to the development of PTS [23, 26]. PTS is a leading determinant of
long-term quality of life in DVT patients and often results
in work disability and substantial costs to patients and
society [27, 28].
Guidance Statement The goals of thrombolytic therapy
are to reduce thrombus burden and (a) for massive and
submassive PE, to reduce mortality and recurrent PE,
relieve symptoms, prevent CTEPH, preserve functional
capacity, and improve quality of life; and (b) for acute
iliofemoral DVT, to relieve symptoms, prevent PTS, improve
quality of life, and in selected patients save life, limb, or
organ.
(2)

(1)

What are the goals of thrombolytic therapy?

Table 1 Guidance questions to
be considered
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What are the risk stratification criteria for thrombolytic therapy for PE and DVT?

What are the major goals of thrombolytic therapy for DVT and PE?
What are the risk stratification criteria for thrombolytic therapy for PE and DVT?
Is systemic thrombolytic therapy recommended for PE and DVT?
When and what types of catheter-directed thrombolysis are recommended for DVT and PE?
How can safety during thrombolytic infusions be optimized?
When should IVC filters be used with thrombolytic therapy?
When should surgical embolectomy be considered?
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Table 2 Goals of thrombolytic therapy for pulmonary embolism
Short-term
Dissolve thromboembolic obstruction of the pulmonary arterial tree to reduce pulmonary vascular resistance
Rapidly resolve right ventricular (RV) pressure overload and improve RV function
Expedite restoration of pulmonary capillary blood flow and effective gas exchange
More quickly resolve symptoms
Prevent early clinical deterioration and mortality in patients with massive and submassive PE
Decrease the risk of recurrent PE by dissolving the reservoir of thrombus that often remains in the lower extremities or pelvis.
Long-term
Prevent the development of CTEPH
Preserve the normal hemodynamic response to exercise

Risk stratification refers to a systematic process of
identifying VTE patients who may benefit from advanced
therapies such as thrombolysis [29].
Risk stratification for acute PE
Risk stratification of patients with acute PE begins with a
careful review of the patient’s presentation, co-morbid
conditions, and physical examination to assess for factors
that increase the risk of death and hemodynamic collapse as
well as bleeding. Acute PE describes a spectrum of clinical
syndromes with varying prognosis [30]. Patients with acute
PE presenting with hypotension, syncope, cardiogenic
shock, cardiac arrest, or respiratory failure define massive
PE and have a high mortality if aggressive treatment is not
instituted [31]. Normotensive patients with acute PE and
evidence of RV dysfunction are classified as having submassive PE and comprise a population at increased risk of
adverse outcomes and early mortality [32].
In addition to the history and physical examination,
electrocardiography, cardiac biomarkers, chest computed
tomography (CT), and echocardiography are important
instruments for risk stratification because they detect RV
dysfunction. The electrocardiogram may be the earliest
indicator of RV dysfunction in the setting of PE. Elevations
in cardiac biomarkers, including troponin and brain-type
natriuretic peptide (BNP) are associated with RV dysfunction and can identify patients at increased risk for
hemodynamic deterioration and early mortality [33]. Cardiac biomarkers, in particular troponin, should be obtained
when acute PE patients present with hemodynamic instability or if there is clinical suspicion for RV dysfunction
[34]. Increasing cardiac troponin levels correspond with
greater risk of PE-related death and all-cause mortality
[35].
RV enlargement on chest CT is defined by RV-diameter-to-LV diameter ratio in excess of 0.9 [36]. The presence
of RV enlargement on chest CT correlates with increased
30-day and 3-month mortality following acute PE [36, 37].
Chest CT is especially useful because the RV is imaged
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during the initial diagnostic scan and no additional imaging
or reformatting is required.
Echocardiography remains the most widely utilized
imaging technique for detection of RV dysfunction in the
setting of PE. Characteristic echocardiographic abnormalities in patients with acute PE include RV dilatation and
hypokinesis, interventricular septal flattening and paradoxical motion toward the left ventricle (LV), abnormal
transmitral Doppler flow profile (represented by the A
wave making a greater contribution to LV diastole than the
E wave), tricuspid regurgitation, pulmonary hypertension
as identified by a peak tricuspid regurgitant jet velocity
greater than 2.6 m/s, and loss of respirophasic collapse of
the inferior vena cava (IVC) [38]. The finding of severe
free wall hypokinesis and apical sparing (McConnell sign)
is specific for acute PE [39]. Echocardiography is suggested in patients with acute PE and clinical evidence of
RV failure, elevated levels of cardiac biomarkers, or
unexpected clinical decompensation.
Guidance Statement For adults, we suggest use of an
integrated risk stratification algorithm that incorporates
the clinical presentation with cardiac biomarkers, chest
CT, and echocardiography (Fig. 1) to guide decisions on

Fig. 1 An integrated algorithm for risk stratification for patients with
acute pulmonary embolism (PE). RV right ventricular; LV left
ventricular; CT computed tomography; IVC inferior vena cava
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escalation to thrombolytic therapy, surgical embolectomy,
or caval filter placement. In children, because prognostic
factors for acute and long-term PE outcomes are not wellestablished and limited clinical trial data are available, we
suggest that decision-making be based on individualized
risk–benefit considerations and patient age, and that future
prospective studies be conducted to inform future pediatric
care.

Risk stratification for acute DVT
For most patients with acute DVT, endovascular or surgical
intervention is not performed to prevent death, but is
electively performed with the goals of improving shortterm symptoms and long-term quality of life. Given the
risks of thrombolytic therapy, careful risk stratification is
important to ensure that only those patients who are most
likely to benefit and least likely to be harmed are treated.
Important factors to routinely consider are summarized
below [25]:
•

•

•

Projected risk of bleeding All patients in whom
thrombolytic therapy is being considered must undergo
careful evaluation for factors that may increase the risk
of bleeding, including (but not limited to) ongoing or
recent active bleeding; recent major surgery, trauma,
pregnancy, CPR, or other invasive procedure; and the
presence of lesions that could bleed in critical areas like
the central nervous system. In general, a very low
threshold should be applied to exclude patients if there
bleeding concerns, unless the patient clearly requires
urgent escalation of therapy to save life, limb, or organ
(see below).
Clinical severity of DVT Urgent thrombolysis is
indicated to prevent life-, limb-, or organ-threatening
complications of acute DVT in situations such as
phlegmasia cerulea dolens or extensive IVC thrombosis
(especially with suprarenal extension which may lead
to fatal PE or acute renal failure). Non-urgent thrombolysis may also be reasonable when initial anticoagulation alone has failed to achieve therapeutic
objectives—either there is major anatomic DVT progression, an increase in clinical severity of DVT, or
patient inability or unwillingness to tolerate ongoing
major DVT symptoms (i.e. pain and swelling that are
not relieved or that limit physical activity). In the latter
situations, a low threshold should be applied to exclude
patients from thrombolytic therapy if there are risk
factors for bleeding, and the patient should be made
aware of the risks, benefits, and alternative approaches.
Anatomic extent of DVT Patients with acute iliofemoral
DVT, defined as involving the iliac vein and/or

•
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common femoral vein with symptom duration 14 days
or less, are at much-increased risk for PTS and
recurrent VTE and therefore appear to represent the
most appropriate candidates for thrombolytic therapy
[30, 40, 41]. In contrast, patients with asymptomatic
DVT or isolated calf DVT should not undergo thrombolytic therapy since the risk of developing PTS is very
low [42]. At present, thrombolytic therapy is discouraged in most patients with DVT that does not extend as
far cephalad as the common femoral vein, and
especially in patients with DVT symptoms of more
than 4 weeks duration (since thrombolytic drugs are not
as effective for clearance of organized thrombus) [22].
Life-expectancy baseline ambulatory capacity, and comorbidities. Patients who are chronically unable to
walk or who have very short life-expectancy are less
likely to benefit meaningfully from aggressive therapy
to prevent PTS. In addition, some patients are likely to
have difficulty in tolerating aggressive intervention—
for example, patients with significant respiratory compromise who cannot lie prone and safely receive
sedation for the procedure.

Guidance Statement Decisions on use of thrombolytic
therapy for acute DVT must be highly individualized to
patient circumstances. For the selection of symptomatic
lower extremity acute proximal DVT patients for whom the
benefits of thrombolysis are most likely to outweigh the
risks, we suggest use of the risk stratification algorithm
presented in Fig. 2.
(3)

Is systemic thrombolytic therapy recommended for
PE and DVT?

Systemic thrombolysis refers to the administration of a
fibrinolytic drug through an intravenous line that is distant
from the target vessel(s). In contemporary VTE practice,
systemic thrombolysis is frequently considered for use in
patients with submassive or massive PE.
Systemic thrombolysis for massive and submassive PE
Since 1970, 16 randomized controlled trials have compared
systemic thrombolysis to anticoagulation alone for the
treatment of acute PE with a mortality endpoint. In the
largest trial of systemic thrombolysis for submassive PE to
date (the PEITHO Study), thrombolysis was shown to
prevent hemodynamic decompensation at the price of an
increased risk of intracranial bleeding [43]. Three recent
meta-analyses aggregated the data from the PEITHO and
other prior trials [17, 44, 45].
Chatterjee et al. analyzed 1061 patients treated with
thrombolysis and 1054 patients treated with anticoagulation alone [17]. This meta-analysis demonstrated systemic
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Fig. 2 Risk stratification for
patients with acute lower
extremity proximal DVT

thrombolysis to be associated with a reduction in all-cause
mortality (2.17 vs. 3.89 %; OR 0.53; 95 % confidence
interval 0.32–0.88) and recurrent PE (1.17 vs. 3.05 %; OR
0.40; 95 % confidence interval 0.22–0.74) compared with
anticoagulation alone, yielding a number needed to treat of
59. The mortality benefit persisted when the analysis was
limited to patients with submassive PE. However, the use
of systemic thrombolysis was also associated with an
increase in major bleeding (9.24 vs. 3.42 %; OR 2.73;
95 % confidence interval 1.91–3.91) and intracranial
bleeding (1.46 vs. 0.19 %; OR 4.78; 95 % confidence
interval 1.78–12.04); the increased major bleeding was
primarily driven by patients [65 years of age.
Nakamura et al. excluded trials if (1) they were conducted
before 1980, (2) they were not presented at a major
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international congress, or (3) they did not clearly consist of
submassive PE patients as defined by right ventricular dysfunction [44]. The results of this meta-analysis (6 trials, 1510
patients) did not identify a mortality benefit for systemic
thrombolysis when applied to patients with submassive PE,
but did identify an increased risk of intracranial bleeding.
In the meta-analysis of Marti et al., 15 trials involving
2057 patients were included [45]. Thrombolysis was
associated with a significant reduction of all-cause mortality (OR 0.59, 95 % CI 0.36–0.96). The mortality
reduction was not statistically significant after the exclusion of studies including massive PE. Thrombolytic therapy was associated with a significant reduction in the
combined endpoint of death or treatment escalation (OR
0.34; 95 % CI 0.22–0.53), PE-related mortality (OR 0.29;
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95 % CI 0.14–0.60) and recurrent PE (OR 0.50; 95 % CI
0.27–0.94). Major bleeding (OR 2.91; 95 % CI 1.95–4.36)
and fatal or intracranial hemorrhage (OR 3.18; 95 % CI
1.25–8.11) were more frequent among patients receiving
thrombolysis.
The data for massive PE are scant, given its lower
incidence in hospital-presenting patients and the practical
difficulty in including them in randomized trials. A pooled
meta-analysis of five studies did find a reduced rate of the
composite endpoint of death or recurrent pulmonary
embolism when thrombolytic therapy was used compared
with anticoagulation alone in the setting of massive PE,
although each individual endpoint failed to reach statistical
significance [46]. Other studies have found that systemic
thrombolytic therapy is associated with a reduced incidence of clinical deterioration, defined variably but typically implying escalation of care (intubation, resuscitation,
or use of invasive rescue interventions), compared with
anticoagulation alone.
Considering all the evidence, the mortality benefit for
submassive PE appears to be largely offset by the risk of
major bleeding, in particular intracranial bleeding.
Guidance Statement Systemic thrombolysis is a reasonable consideration for selected patients with acute PE
who are hemodynamically unstable (massive PE) or who
have evidence of RV dysfunction (submassive PE), and who
do not have contraindications to the use of thrombolytic
drugs. The benefit to risk ratio may be more favorable for
patients with massive PE. For submassive PE, the decision
to use systemic thrombolysis should be made on an individual patient basis, with careful consideration of the
patient’s age, co-morbidities, severity of RV dysfunction,
degree of biomarker elevation, respiratory status, bleeding
risk, and likelihood of clinical deterioration based upon
his/her observed clinical course.
Systemic thrombolysis for DVT
The use of systemic thrombolysis to treat acute proximal
DVT has been systematically assessed in randomized
clinical trials. Although evidence of partial clot removal
efficacy was demonstrated, major bleeding was increased
by 3–4 times over anticoagulation alone [47]. Catheterdirected methods now enable superior venous thrombus
removal efficacy with reduced fibrinolytic drug dose.
Guidance Statement Systemic thrombolysis is not suggested for DVT therapy.
(4)

When and what types of catheter-directed thrombolysis are recommended for PE and DVT?

Catheter-directed thrombolysis (CDT) refers to direct
intra-thrombus administration of a fibrinolytic drug via a

73

catheter or device that is embedded within the thrombus
using imaging guidance [48]. The theoretical advantages of
intra-thrombus infusion are several: (1) the ability to
achieve a high intra-thrombus drug concentration and
avoid bypass of the drug around occluded venous segments
via collaterals can improve clot removal efficacy; (2) the
addition of mechanical thrombus disruption with some
drug delivery methods may further enhance pharmacological dissolution of thrombus; (3) the improved efficacy may
enable reduced thrombolytic drug dose, treatment time,
hospital resource use, and bleeding complications; and (4)
for DVT, catheter access into the venous system may
enable treatment of underlying venous anatomic abnormalities, which may help to reduce the risk of recurrent
DVT.
Catheter-directed thrombolysis for acute PE
Concern over the risk of intracranial hemorrhage has
dampened clinician enthusiasm for full-dose systemic
thrombolysis, and has driven interest in catheter-directed
techniques that utilize lower doses of thrombolytic agent
thereby potentially lowering the bleeding risk. In a systematic review of 594 patients from 35 studies who
received a heterogeneous array of catheter-based therapies,
clinical success was achieved in 87 % of patients undergoing catheter-directed therapy with a relatively low frequency of major complications [49]. It should be noted,
however, that the data in this review were derived predominantly from case series and small cohort studies,
precluding firm conclusions from being drawn.
At present, the use of catheter-directed therapy for acute
PE may be considered for hemodynamically compromised
patients or those with significant RV dysfunction when
systemic thrombolysis has failed or as an alternative to
systemic thrombolytic therapy, if local expertise is available [50–53]. For patients with absolute contraindications
to thrombolysis, catheter-assisted embolectomy without
thrombolysis may be used, but the proportion of patients
who are expected to benefit is uncertain and is likely lower
than for drug-based CDT [51, 52]. If catheter-directed
therapy is incorporated into local PE treatment algorithms,
we recommend close monitoring of the actual outcomes
achieved since the prospective studies evaluating its use are
limited in size and scope (just one RCT with 59 patients),
and results may vary from institution to institution.
In recent years, ultrasound-assisted CDT has undergone
prospective evaluation for the treatment of patients with
acute PE. The EkoSonic Endovascular System (EKOS, a
BTG International Group company, Bothell, WA, USA)
uses high-frequency, low-intensity ultrasound to disaggregate fibrin fibers, potentially allowing greater penetration
of the thrombolytic drug. In a randomized controlled trial
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of 59 patients with submassive PE in Europe, ultrasoundassisted CDT with 20 mg total dose rt-PA plus anticoagulation reduced the RV/LV diameter ratio from baseline to
24 h to a greater extent than anticoagulation alone [54]. No
patients undergoing ultrasound-assisted CDT died, suffered
recurrent VTE, or developed major bleeding. A subsequent
prospective, single-arm, multicenter study of ultrasoundassisted CDT in 150 patients with acute massive or submassive PE demonstrated a 25 % reduction in mean RV/
LV diameter ratio from pre-procedure to 48 h post-procedure, a 30 % decrease in mean pulmonary artery systolic
pressure from baseline to procedure completion, and a
30 % improvement in the modified Miller obstruction
index from baseline to 48 h post-procedure [55]. Major
bleeding occurred in 10 % of patients with only one patient
suffering a Global Use of Strategies to Open Occluded
Coronary Arteries (GUSTO) severe or life-threatening
bleed. No patients suffered intracranial hemorrhage. On
May 21, 2014, based on the data from this trial and prior
studies, the EkoSonic Endovascular System received
FDA approval for the treatment of PE. However, data from
larger randomized trials will be needed to determine if
ultrasound-assisted CDT or any catheter-based method
should be routinely employed for the management of
submassive PE on the basis of mortality reduction or prevention of long-term PE sequelae.
Guidance Statement CDT may be reasonable to employ
in centers with the available expertise for patients with
acute PE who are hemodynamically unstable (massive PE)
or who have evidence of right ventricular dysfunction
(submassive PE), and who do not have contraindications to
the use of thrombolytic drugs. CDT may enable the use of
lower doses of thrombolytic drug than systemic thrombolysis. For patients with relative contraindications to
thrombolytic drugs, either surgical embolectomy or CDT
may be considered, depending on the specific nature of the
contraindication, the availability of local endovascular or
surgical expertise, and the ability to rapidly activate the
applicable procedure team.

S. Vedantham et al.

residual thrombus using mechanical thrombectomy; and
(e) treatment of underlying venous stenosis (e.g. May–
Thurner syndrome) with balloon angioplasty or stent
placement [25, 56].
Although the broad range of specific methods is beyond
the scope of this article to discuss, they are categorized
below into 3 groups, with observed results briefly
summarized:
•

•

Catheter-directed thrombolysis for acute DVT
The basic steps in performing CDT and related procedures
are: (a) ultrasound-guided venous access using a micropuncture system to reduce the risk of access site bleeding;
(b) catheter venography to map the extent of thrombus;
(c) intra-thrombus delivery of a thrombolytic drug—this
may be accomplished via slow infusion through a traditional multi-sidehole infusion catheter or ultrasound-emitting infusion catheter, or by bolus drug delivery and
dispersion through a catheter-based drug delivery device;
(d) re-assessment with venography, and clean-up of
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Drug-only CDT With drug-only CDT, successful lysis
of [50 % of the thrombus and restoration of venous
patency are expected in 80–90 % of patients in whom
symptom duration is \14 days [25]. In a rigorously
conducted multicenter RCT (the CAVENT Study) of
patients with DVT involving the iliac and/or upper
femoral venous system, CDT using rt-PA infusions (at
0.01 mg/kg/hr for up to 4 days) with anticoagulant
therapy was associated with a 26 % relative reduction
in the risk of PTS over 2 years (41.1 vs. 55.6 %,
p = 0.04) compared with anticoagulant therapy alone
[57]. The amount of residual thrombus post-CDT
correlated with venous patency rates at 24 months
follow-up (p = 0.04), and venous patency at 6 and
24 months correlated with freedom from PTS
(p \ 0.001) [23]. In this study, 3.2 % of patients
receiving CDT developed a major bleed, including
one patient who required surgery and another who
received a blood transfusion, but there were no
intracranial bleeds or deaths. Limitations of this study
include its modest sample size (efficacy outcomes
reported in 189 patients) and geographical limitation
(four treatment centers in Norway).
Device-only percutaneous mechanical thrombectomy
(PMT) Published experience with PMT (without use of
a fibrinolytic drug) for DVT has been disappointing. In
general, the use of aspirating-type devices has not
removed sufficient thrombus to be therapeutically
useful [58, 59], and use of non-aspirating devices can
result in symptomatic PE [60, 61]. Although new
aspirating devices are now available, prospective data
on their use is lacking at present. Hence, the use of
stand-alone PMT is strongly discouraged unless a
patient with clinically severe DVT is felt to absolutely
require therapy and fibrinolytic drugs cannot be given.
Drug plus device pharmacomechanical CDT (PCDT)
Retrospective comparative studies have documented
that the use of adjunctive PMT along with infusion
CDT is associated with (a) initial treatment safety and
efficacy at least as good as infusion-only CDT—
observational studies suggest 3–5 % rates of major
bleeding; (b) 40–50 % reductions in drug dose and
treatment time compared with infusion-only CDT; and
(c) markedly reduced hospital stays and intensive care
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•

unit utilization [62–65]. As a result, clinical practice in
the US and many other countries has largely evolved
towards the use of PCDT. Some PCDT methods (e.g.
isolated thrombolysis with the Trellis device or powerpulse thrombolysis with the AngioJet device) can
enable treatment of selected patients in a single
procedure session, further minimizing patient exposure
to the thrombolytic drug [66, 67]. However, there are
no completed, high-quality RCTs evaluating PCDT.
The ongoing NIH-sponsored ATTRACT Trial (NCT
0070035) and other studies may soon provide rigorous
data on the benefit-to-risk ratio of PCDT [68]. In
adolescents, limited single-institution prospective data
on PCDT for occlusive iliofemoral DVT provide proofof-concept support that this approach can be feasibly
performed with low complication rates and PTS rates
that appear favourable [69].
Ultrasound-assisted CDT As noted above, intra-thrombus drug delivery can also be performed in conjunction
with the delivery of low-power ultrasound energy into
the thrombus using the EkoSonic Endovascular System. Venous thrombus removal efficacy appears to be
comparable to that of infusion-only CDT. A retrospective comparative study did not find an added benefit to
use of the ultrasound catheter compared with a standard
multi-sidehole catheter, but this comparison had
methodological limitations [70]. To date, there have
been no well-designed prospective studies to determine
the incremental value of the added ultrasound. An
ongoing multicenter RCT is ongoing in Europe to
determine if ultrasound-assisted CDT is superior to
anticoagulation alone for the prevention of PTS.
To date, no thrombolytic drug is FDA approved for the
treatment of DVT. Although the use of reteplase and
tenecteplase has been reported in small case series, the
vast majority of reported experience has been with rtPA. For infusion CDT with rt-PA, currently accepted
dosing is weight-based administration at 0.01 mg/kg/hr,
not to exceed 1.0 mg/hr [25, 57].

Guidance Statement When acute DVT is treated, the
use of pharmacomechanical CDT is suggested over the use
of infusion-only CDT since it is likely to reduce treatment
time and thrombolytic dose. When rt-PA is used, weightbased administration of 0.01 mg/kg/hr, not to exceed
1.0 mg/hr, is suggested. The use of stand-alone PMT is
strongly discouraged unless a patient with clinically severe
DVT is felt to absolutely require therapy and fibrinolytic
drugs cannot be given.
(5)

How can safety during thrombolytic infusions be
optimized?
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Physicians who employ thrombolytic drugs must realize
that their therapeutic window of safety is extremely narrow. Careful patient selection is paramount, and in particular the review of a patient’s history for factors that may
connote an increased risk of bleeding complications must
be performed with utmost rigor. Since the venous access
site has been the most common site of bleeding, venous
punctures for CDT should be performed with ultrasound
guidance to reduce the risk of inadvertent arterial punctures. Patients must be monitored carefully in a hospital
area where frequent nursing contact can be expected; in
most hospitals this may be an intensive care unit or intermediate-level care unit. Excellent communication among
the physicians, procedure area nurses, and floor/ICU nurses
is essential to ensure that transitions of care do not introduce the potential for errors. Temporary or permanent
cessation of the thrombolytic infusion should be considered
if active bleeding occurs, if there is a drop in hematocrit, if
the PTT or anti-Xa level is supratherapeutic, or if the fibrinogen level drops to less than 100 mg/dl. For patients
undergoing CDT for DVT, venographic re-checks should
be performed no less frequently than every 24 h. For adults
undergoing CDT, infusion for [36–48 h is strongly discouraged and should occur only in unusual cases.
Guidance Statement Safety during thrombolytic infusions can be optimized with rigorous patient selection, use
of ultrasound guidance for venous punctures, and close
patient monitoring.
(6)

When should IVC filters be used with thrombolytic
therapy?

IVC filter insertion is generally considered for VTE
patients who cannot receive anticoagulation or who have
suffered a recurrent VTE despite therapeutic anticoagulation
[53]. However, IVC filters may also be placed in patients
who are receiving anticoagulation but in whom there is
concern that a subsequent PE would be fatal. In a sub-analysis of 108 patients with massive PE within the International
Cooperative Pulmonary Embolism Registry (ICOPER), 10
out of 11 patients survived until 90 days, and none developed
recurrent PE [71]. In this study, IVC filter placement was
associated with a hazard ratio of 0.12 (95 % CI 0.02–0.85)
for death following massive PE. In a separate analysis of
hospital discharge data, unstable patients, irrespective of
whether they received thrombolytics, had a lower case
fatality rate if they received an IVC filter [72]. It should be
noted that these findings represent non-randomized data that
may have been subject to bias; nevertheless, they suggest that
in selected patients with poor cardiopulmonary reserve who
cannot tolerate another embolic event, IVC filter insertion
may indeed be of benefit.
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In the same hospital discharge data analysis, the authors
found a lower case fatality rate for patients who received a
filter in stable patients who underwent systemic thrombolysis compared with those who did not receive a filter
and underwent systemic thrombolysis [72]. It is important
to note that the definition of ‘‘instability’’ in this study was
an ICD-9 code corresponding to ‘‘shock’’ or ‘‘ventilator
dependence’’, so the term ‘‘stability’’ may have included
massive PE patients who were not in frank shock. Other
than these data, there is no convincing evidence for or
against the placement of IVC filters in patients with submassive PE.
For patients receiving thrombolytic therapy for DVT,
the incidence of symptomatic PE during drug-only CDT
does not appear to exceed that observed in patients who
receive anticoagulant therapy alone [22, 25]. In a multicenter RCT in which 92 patients received drug-only CDT,
there were no cases of procedure-related symptomatic PE
[57]. Whether or not an IVC filter enhances safety for
patients undergoing single-session PCDT, which may
involve greater on-table thrombus manipulation, is not
clear. The long-term risks of retrievable filters include
device migration, embolization, and fracture, and recurrent
DVT (which could increase the risk of PTS).

mortality in the thrombolytic group [75]. In a single-center
retrospective analysis of 47 patients undergoing pulmonary
embolectomy for both massive and submassive PE, there
were only 3 deaths, suggesting that surgery can provide
reasonably good outcomes if significant experience is
locally available and patients are carefully selected [76].
Multidisciplinary PE response teams have emerged
given the various treatment options involving different
areas of expertise [77]. Team members may include pulmonologists, cardiologists, interventional radiologists,
cardiothoracic surgeons, and others. The purpose of such
teams is to rapidly assess and stratify patients presenting
with acute PE and determine whether and what type of
therapeutic escalation beyond anticoagulation is indicated.
A key component of these teams is an early multi-disciplinary consensus on the best option for an individual
patient, taking into account thrombus burden and location,
imaging and biomarker results, bleeding risk, and clinical
presentation. Currently, robust outcome data are lacking
regarding the efficacy of such teams. Given that early
stratification can identify patients who are likely to
decompensate and need treatment escalation, we suggest
early communication between treating physicians and local
medical, interventional, and surgical specialists.

Guidance Statement The routine placement of IVC filters before infusion CDT is not suggested. Placement of a
retrievable filter may be reasonable for patients at particularly high risk of major morbidity due to clinical PE
during CDT, such as patients with poor cardiopulmonary
reserve, especially if single-session PCDT or stand-alone
PMT without pharmacologic CDT is being employed. Once
thrombolysis is completed, IVC filters should ideally be
removed as soon as the period of major PE risk has passed.

Guidance Statement Comparative data are limited, and
it is not currently possible to make firm conclusions about
when and in which patients embolectomy should be performed. Based on the limited data and if local surgical
expertise is available, it is suggested that embolectomy be
considered for massive or submassive PE patients who fail
or cannot receive systemic thrombolysis but who have not
suffered a cardiac arrest, especially if intra-cardiac
thrombus (‘‘in transit’’) is present.

(7)

When should surgical embolectomy be considered?

Surgical embolectomy is an important option in the
treatment of hemodynamically significant pulmonary
embolism. There has been a steady increase in survival
over the past few decades, secondary to improved techniques and patient selection. This is reflected by the
reduced mortality from 1985 to 2005 (20 %) compared
with the time period before 1985 (32 %) [73]. This same
review demonstrated a much higher mortality in patients
who were in cardiac arrest prior to surgery (59 %) versus
those who were not (29 %). As might be expected, patients
who have surgery initiated when hemodynamically
stable appear to have lower operative mortality than
patients who are ventilator dependent or in cardiogenic
shock [74]. In a single center registry in which 40 patients
who did not respond to initial systemic thrombolysis
underwent either a second thrombolytic administration or a
pulmonary embolectomy, there was a trend towards higher
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Conclusion
Viewing acute VTE as a chronic disease
Patients who are considered for, or undergo, thrombolytic
therapy for an episode of acute DVT or PE remain at risk
for long-term sequelae. Recurrent VTE has long been
recognized as an ongoing risk. However, patients surviving
an acute PE event also place substantial importance on
avoiding chronic complications and symptoms in the following months to years [21]. Such concerns are justified
since [40 % of patients assessed 3.6 years after their acute
PE have significantly worse generic quality of life than
age- and sex- adjusted population norms [78]. Exercise
tolerance also appears to be worse in patients who have
suffered submassive PE [79]. Likewise, the occurrence and
severity of PTS have been shown to represent a DVT
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Table 3 Summary of guidance statements
Question

Guidance statement

(1) What are the major goals of thrombolytic therapy
for DVT and PE?

The goals of thrombolytic therapy are to reduce thrombus burden and (a) for massive
and submassive PE, to reduce mortality and recurrent PE, relieve symptoms, prevent
CTEPH, preserve functional capacity, and improve quality of life; and (b) for acute
iliofemoral DVT, to relieve symptoms, prevent PTS, improve quality of life, and in
selected patients save life, limb, or organ

(2a) What are the risk stratification criteria for
thrombolytic therapy for PE?

For adults, we suggest use of an integrated risk stratification algorithm that incorporates
the clinical presentation with cardiac biomarkers, chest CT, and echocardiography
(Fig. 1) to guide decisions on escalation to thrombolytic therapy, surgical
embolectomy, or caval filter placement. In children, because prognostic factors for
acute and long-term PE outcomes are not well-established and limited clinical trial
data are available, we suggest that decision-making be based on individualized riskbenefit considerations and patient age, and that future prospective studies be
conducted to inform future pediatric care

(2b) What are the risk stratification criteria for
thrombolytic therapy for DVT?

Decisions on use of thrombolytic therapy for acute DVT must be highly individualized
to patient circumstances. For the selection of symptomatic lower extremity acute
proximal DVT patients for whom the benefits of thrombolysis are most likely to
outweigh the risks, we suggest use of the risk stratification algorithm presented in
Fig. 2

(3a) Is systemic thrombolytic therapy recommended
for PE?

Systemic thrombolysis is a reasonable consideration for selected patients with acute PE
who are hemodynamically unstable (massive PE) or who have evidence of RV
dysfunction (submassive PE), and who do not have contraindications to the use of
thrombolytic drugs. The benefit to risk ratio may be more favorable for patients with
massive PE. For submassive PE, the decision to use systemic thrombolysis should be
made on an individual patient basis, with careful consideration of the patient’s age,
co-morbidities, severity of RV dysfunction, degree of biomarker elevation,
respiratory status, bleeding risk, and likelihood of clinical deterioration based upon
his/her observed clinical course

(3b) Is systemic thrombolytic therapy recommended
for DVT?

Systemic thrombolysis is not recommended for DVT therapy

(4a) When and what types of catheter-directed
thrombolysis are recommended for PE?

CDT may be reasonable to employ in centers with the available expertise for patients
with acute PE who are hemodynamically unstable (massive PE) or who have
evidence of right ventricular dysfunction (submassive PE), and who do not have
contraindications to the use of thrombolytic drugs. CDT may enable the use of lower
doses of thrombolytic drug than systemic thrombolysis. For patients with
contraindications to thrombolytic drugs, either surgical thrombectomy or CDT may
be considered, depending on the specific nature of the contraindication, the
availability of local endovascular or surgical expertise, and the ability to rapidly
activate the applicable procedure team

(4b) When and what types of catheter-directed
thrombolysis are recommended for DVT?

When acute DVT is treated, the use of pharmacomechanical CDT is suggested over the
use of infusion-only CDT since it is likely to reduce treatment time and thrombolytic
dose. When rt-PA is used, weight-based administration of 0.01 mg/kg/hr, not to
exceed 1.0 mg/hr, is recommended. The use of stand-alone PMT is strongly
discouraged unless a patient with clinically severe DVT is felt to absolutely require
therapy and fibrinolytic drugs cannot be given

(5) How can safety during thrombolytic infusions be
optimized?

Safety during thrombolytic infusions can be optimized with rigorous patient selection,
use of ultrasound guidance for venous punctures, and close patient monitoring.

(6) When should IVC filters be used with thrombolytic
therapy?

The routine placement of IVC filters before infusion CDT is not recommended.
Placement of a retrievable filter may be reasonable for patients at particularly high
risk of major morbidity due to clinical PE during CDT, such as patients with poor
cardiopulmonary reserve, especially if single-session PCDT or stand-alone PMT
without pharmacologic CDT is being employed. Once thrombolysis is completed,
IVC filters should ideally be removed as soon as the period of major PE risk has
passed

(7) When should surgical embolectomy be considered?

Comparative data are limited, and it is not currently possible to make firm conclusions
about when and in which patients embolectomy should be performed. Based on the
limited data and if local surgical expertise is available, it is suggested that
embolectomy be considered for massive or submassive PE patients who fail or cannot
receive systemic thrombolysis but who have not suffered a cardiac arrest, especially if
intra-cardiac thrombus (‘‘in transit’’) is present
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patient’s primary determinant of quality of life over 2 years
follow-up [27]. The anxiety and psychological trauma
caused by an episode of acute PE or DVT also cannot be
discounted [80].
Therefore, considering also the limited evidence foundation underlying many recommendations and the many
unknowns concerning their generalizability to specific
practice settings, we strongly recommend that physicians
systematically monitor the actual clinical outcomes that are
achieved in their local practices in applying the above
clinical recommendations, and make any needed adjustments. In doing so, we recommend that comparable
attention be given to short-term outcomes (e.g. survival,
need for treatment escalation) and to long-term outcomes
(e.g. functional status and QOL), and that future studies
evaluate strategies to reduce psychological and/or physical
adverse outcomes following VTE. Referral of patients to
local or web-based PE and DVT support groups and patient
education sites may assist patients in their understanding
of, and emotional recovery from, VTE. Table 3 contains a
summary of all guidance suggestions.
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